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ABSTRACT Research on the association between chronic bronchitis and chronic obstructive pulmonary
disease (COPD) exacerbations has led to discordant results. Furthermore, the impact of chronic bronchitis
on mortality in COPD subjects is unclear.
Within the Rotterdam Study, a population-based cohort study of subjects aged ⩾45 years, chronic
bronchitis was defined as having a productive cough for ⩾3 months per year for two consecutive years.
Linear, logistic regression and Cox proportional hazard models were adjusted for age, sex and pack-years.
Out of 972 included COPD subjects, 752 had no chronic phlegm production (CB−) and 220 had chronic
phlegm production, of whom 172 met the definition of chronic bronchitis (CB+). CB+ subjects were older, more
frequently current smokers and had more pack-years than CB− subjects. During a median 6.5 years of follow-
up, CB+ subjects had greater decline in lung function (−38 mL·year−1, 95% CI −61.7–−14.6; p=0.024). CB+
subjects had an increased risk of frequent exacerbations (OR 4.0, 95% CI 2.7–5.9; p<0.001). In females, survival
was significantly worse in CB+ subjects compared to CB− subjects. Regarding cause-specific mortality, CB+
subjects had an increased risk of respiratory mortality (hazard ratio 2.16, 95% CI 1.12–4.17; p=0.002).
COPD subjects with chronic bronchitis have an increased risk of exacerbations and respiratory mortality
compared to COPD subjects without chronic phlegm production.
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Introduction
Progressive, incompletely reversible airflow limitation is the main characteristic of chronic obstructive
pulmonary disease (COPD) [1]. Clinical presentation, response to therapy and disease progression are
heterogeneous among patients with COPD [1]. Patients with COPD suffer to varying degrees from chronic
cough, expectoration of phlegm, dyspnoea and a variety of extrapulmonary symptoms. Identifying and
studying subgroups of patients with similar traits within the COPD syndrome can aid in guiding more
individualised therapy and assessment of prognosis [2]. Several COPD phenotypes have been proposed,
but only a few have been validated [3]. One of these COPD phenotypes is the chronic bronchitis (CB)
phenotype, which is generally defined as patients with COPD who experience chronic cough and sputum
production for ⩾3 months per year for two consecutive years [4].
Observational studies linking the chronic bronchitis phenotype in COPD to outcomes have generated
inconsistent results regarding exacerbations and mortality. Both outcomes are crucial since they have a
substantial impact on the burden of disease [1]. Although COPD is a chronic disease, acute exacerbations
and the rate at which they occur determine the progression of the disease [5]. Because COPD
exacerbations have been associated with impaired quality of life [6, 7], accelerated deterioration of lung
function [8, 9], increased risk of hospital admission [10] and increase in mortality [11], they have an
important impact on the healthcare-related costs [3]. Two large-scale studies in Global Initiative for
Chronic Obstructive Lung Disease (GOLD) stage II–IV COPD patients with ⩾10 pack-years of smoking
history have reported on the association between chronic bronchitis and exacerbations, with opposing
results: the Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE)
study (n=2138) did not find an association between chronic bronchitis and (medically treated) COPD
exacerbations during the first year of follow-up, whereas the COPDGene study (n=1061) detected a strong
association between chronic bronchitis and self-reported exacerbation history [12–14]. Other smaller
patient-based studies contribute to these discordant results by observing the absence as well as the
presence of an association between chronic bronchitis and exacerbation history [15–18]. In contrast,
observations from population-based studies are scarce and evaluated only COPD hospitalisations or a
self-reported exacerbation history [8, 19].
In addition, the effect of the presence of chronic bronchitis in COPD patients on mortality risk is unclear.
Although several papers observed an increased mortality risk in COPD patients with chronic bronchitis, it
is not clear whether this subgroup of COPD patients is more prone to all-cause mortality or specifically to
COPD-related respiratory mortality [20–22]. Furthermore, several studies found different effects of the
presence of chronic bronchitis on mortality in males and females [22].
Since previous studies on the association between chronic bronchitis and exacerbations were mainly
cross-sectional, clinic-based and provided discordant results, we aimed to investigate the impact of chronic
bronchitis on the course of COPD including exacerbations and mortality risk in a prospective
population-based cohort study with long-term follow-up, the Rotterdam Study [23].
Methods
Study design
The present study is embedded within the Rotterdam Study, a population-based cohort study comprising
almost 15000 participants aged ⩾45 years aiming to assess the occurrence of, and risk factors for, chronic
diseases in the elderly [23]. The study started in 1989 and all participants are invited every 3–4 years to
the research centre for follow-up examinations, including spirometry. All participants with prevalent
COPD and who completed questionnaires on chronic bronchitis during the examination rounds
performed between 2001 and 2008 were included. Follow-up time was defined as the time period between
the subject’s visit to the examination round, and death or end of study period (e.g. January 1, 2013 for the
validation of (cause-specific) death), whichever came first. The medical ethics committee of the Erasmus
Medical Centre (Rotterdam, the Netherlands), and the review board of the Netherlands Ministry of
Health, Welfare and Sports (1068889-159521-PG) approved the study. Participants gave written informed
consent.
Assessment of COPD and lung function decline
The diagnosis of COPD was based on an obstructive prebronchodilator spirometry examination according
to the modified GOLD criteria (forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) <0.7)
or, in the absence of an interpretable spirometry measurement at the research centre, based on diagnosis
by a respiratory physician or general practitioner combining clinical history, physical examination and
spirometry [24]. Spirometry was performed between 2001 and 2008 using a SpiroPro portable spirometer
(Erich Jaeger, Hoechberg, Germany) and from 2009 onwards using a MasterScreen PFT Pro (CareFusion,
San Diego, CA, USA) by trained paramedical personnel according to the American Thoracic Society/
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European Respiratory Society guidelines [25]. Although reversibility tests were not performed in this
population-based setting, physician-diagnosed and questionnaire-based asthmatics were excluded. Lung
function decline per year was calculated by dividing the difference of the two FEV1 (in millilitres)
measurements by the years (days/365.25) between the two measurements. The incident COPD date was
defined as the date of the first obstructive lung function or the date of COPD diagnosis in the medical
reports or the date of the first prescription of COPD medication, whichever came first.
Assessment of chronic bronchitis
Chronic bronchitis was assessed by questionnaire and defined as having a productive cough for
⩾3 months a year during the past 2 years. More specifically, all subjects were questioned [1] “Did you
cough nearly daily for three consecutive months during the last 2 years?” and [2] “Did you cough up
phlegm nearly daily for three consecutive months during the last 2 years?”. Subjects answering negatively
to the second question were defined as having no chronic phlegm production (CB−). Subjects answering
positively to the second question were considered to have chronic phlegm production, but were only
defined as having chronic bronchitis when they answered both questions positively (CB+).
Assessment of exacerbations
All COPD subjects were prospectively followed for the onset of exacerbations from their examination visit
until death or end of study period (e.g. January 1, 2011 for the validation of exacerbations). Moderate
COPD exacerbations were defined as acute episodes of worsening symptoms needing a course of steroids
and/or antibiotics. Complete information on all filled prescriptions on a day-to-day basis was obtained in
automated format from pharmacies and further validated.
Severe COPD exacerbations were defined as exacerbations requiring a hospitalisation due to COPD. All
hospital admissions were continuously registered in the Dutch medical registry and further validated. The
exacerbation rate of each patient was defined as the ratio of the total number of exacerbations over the
total follow-up time in that patient. COPD subjects with frequent exacerbations were determined as
subjects who had at least two (rounded) moderate or severe exacerbations on average per year during
follow-up.
Assessment of quality of life and mortality
Quality of life was based on the EuroQol five-dimension questionnaire (www.euroqol.org; eight questions
until 2006; five questions from 2006 onwards), which measures how satisfied/troubled participants are in
terms of mobility, ability and activity, self-care, pain and anxiety. A score out of 100 was calculated as the
weighted average of scores (minimum=unsatisfied/seriously troubled; maximum=very satisfied/not
troubled at all) given to the individual questions. Information on vital status was obtained from general
practitioners and from municipal records. Causes of death during follow-up were coded according to the
International Classification of Diseases (ICD)-10 [26]. The following categories were applied: pulmonary
mortality (ICD-10: J15–J44), cardiac mortality (ICD-10: I21–I73, R96), death from bronchial carcinoma
(ICD-10: C34), death from other malignancies (ICD-10: C15–C96 except C34) and other causes of death
(ICD-10: all other codes used).
Statistical analyses
Differences between subjects with and without chronic bronchitis were studied using the Mann–Whitney
U-test for continuous variables and Chi-squared test for categorical variables. Logistic and linear regression
models were used to calculate the risk of frequent exacerbations and lung function decline, respectively.
Cox hazard regression models were used to calculate the time to (cause-specific) death. Models were
adjusted for covariates which changed the point estimate of chronic bronchitis on frequent exacerbations
by ⩾5%, i.e. age, sex and pack-years of cigarette smoking. Missing pack-years were considered not missing
at random and therefore were not imputed. Analyses were stratified according to sex, severity of airflow
limitation and the presence or absence of an interpretable lung function measurement at baseline.
Sensitivity analyses were performed by extending the CB+ group meeting the strict definition towards the
broader definition of chronic phlegm production. Statistical analyses were performed using SPSS (version
23.0 for Windows; IBM, North Castle, NY, USA).
Results
Patient population
Out of 972 COPD subjects included in the cohort study, 752 subjects with COPD had no chronic phlegm
production (CB−) and 220 subjects had chronic phlegm production, of whom 172 (78%) met the strict
criteria of chronic bronchitis (CB+) (figure 1). CB+ COPD subjects were older, more frequently current
smokers and had a higher number of pack-years of cigarette smoking (table 1). Furthermore, COPD
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subjects with chronic bronchitis had a worse lung function at baseline than COPD subjects without
chronic bronchitis (table 1). In addition, quality of life was significantly worse in COPD subjects suffering
from chronic bronchitis (table 1). Descriptives and analyses performed when extending the CB+ group of
TABLE 1 Baseline characteristics of chronic obstructive pulmonary disease subjects without
chronic bronchitis (CB−) and with chronic bronchitis (CB+)
CB− CB+ p-value
Subjects n 752 172
Age years 70.5 (15.2) 74.1 (13.6) 0.004
Male 380 (50.5%) 96 (55.8%) 0.211
Smoking status 0.005
Never-smoker 134 (17.8%) 17 (9.9%)
Former smoker 407 (54.1%) 89 (51.7%)
Current smoker 211 (28.1%) 66 (38.4%)
Cigarette smoking pack-years 23.0 (41.2) 30.6 (35.1) <0.001
Height m 1.69 (0.14) 1.68 (0.12) 0.529
Weight kg 76.7 (18.8) 74.8 (17.3) 0.082
BMI kg·m−2 26.6 (5.3) 26.0 (5.5) 0.093
FEV1 L 2.0 (1.1) 1.8 (0.9) <0.001
FEV1 % pred 82.0 (26.7) 70.5 (27.8) <0.001
FVC L 3.1 (1.6) 2.9 (1.4) 0.034
FVC % pred 101.0 (29.5) 91.9 (33.0) 0.008
FEV1/FVC % 65.4 (7.0) 61.0 (10.0) <0.001
Quality of life % 80.0 (21.9) 71.9 (31.3) <0.001
Data are presented as median (interquartile range) unless otherwise stated. Quality of life was based on
the EuroQol five-dimensions questionnaire (EQ-5D; www.euroqol.org) measuring how satisfied/troubled
participants are in terms of mobility, ability and activity, self-care, pain and anxiety. A score out of 100 was
calculated as the weighted average of scores (minimum=unsatisfied/seriously troubled; maximum=very
satisfied/not troubled at all) given to the individual questions. Data were missing on pack-years in 46
subjects, height/weight/BMI in 43 subjects, interpretable baseline lung function measurement in 330
subjects and quality of life in 12 subjects. BMI: body mass index; FEV1: forced expiratory volume in 1 s;
FVC: forced vital capacity.
FIGURE 1 Study flow. For additional
cohort information see [23]. COPD:
chronic obstructive pulmonary
disease; RS: Rotterdam Study
fourth examination in cohort I/
second examination in cohort II/
first examination in cohort III.
997 COPD subjects at time 
of visit RS-I-4/II-2/III-1
25 subjects without data on 
the presence of chronic 
bronchitis
972 COPD subjects
220 COPD subjects with 
chronic phlegm production
752 COPD subjects without
chronic bronchitis (CB–)
172 COPD subjects 
with productive cough 
for ≥3 months 
a year during the past 
2 years (CB+)
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172 subjects meeting the strict definition to the 220 subjects with chronic phlegm production are provided
in the online supplementary material.
Impact of chronic bronchitis on lung function and exacerbation rate
281 out of 972 COPD subjects had an interpretable lung function measurement taken between 2002 and
2008 and a second one between 2009 and 2014. During this median (interquartile range (IQR)) 6.5
(0.8) years of follow-up, COPD subjects with chronic bronchitis had a 38.2 mL per year greater decline in
FEV1 than COPD subjects without chronic bronchitis (95% CI −61.7–−14.6 mL) adjusted for age, sex and
pack-years of cigarette smoking (table 2). The excess decline in FEV1 due to chronic bronchitis was
42.8 mL·year−1 (95% CI −78.1–−7.6 mL·year−1) for male COPD CB+ subjects and 36.1 mL·year−1 (95% CI
−67.1–−5.2 mL·year−1) for female COPD CB+ subjects compared to male and female COPD CB− subjects,
respectively (table 2). Stratified analyses according to the severity of airflow limitation (i.e. FEV1 ⩾80%
predicted or <80% pred) are provided in the online supplementary material. Chronic bronchitis was
significantly associated with lung function decline, both in subjects with mild airflow limitation and in
subjects with moderate to severe airflow limitation (although the per-millilitre decline was more
pronounced in those with milder airflow limitation at baseline) (online supplementary table S2).
During a median (IQR) 5.4 (3.8) years of exacerbation follow-up (until January 1, 2011), COPD
CB+subjects had a three times higher median (IQR) rate of moderate to severe exacerbations per year (0.99
(1.78) exacerbations per year in the COPD CB+ group versus 0.33 (0.85) exacerbations per year in the
COPD CB− group; p<0.001). Additionally, the percentage of COPD subjects who experienced at least one
severe exacerbation during follow-up was higher for CB+ subjects compared to CB− subjects (20.3% versus
7.0%, respectively; p<0.001). Adjusted for age, sex and pack-years of cigarette smoking, COPD CB+
subjects had a fourfold increased risk (OR 4.0, 95% CI 2.7–5.9) of frequent exacerbations (two or more
moderate or severe exacerbations per year) (table 3). The odds ratio of frequent exacerbations was 3.11
(95% CI 1.82–5.31) for male CB+ subjects and 5.10 (95% CI 2.83–9.20) for female CB+ subjects, compared
to male and female COPD CB− subjects, respectively (table 3). Moderate to severe COPD CB+ subjects
had a fourfold increased risk of frequent exacerbations compared to moderate to severe COPD CB−
subjects (online supplementary table S3). In COPD subjects with mild airflow limitation, the effect was
less pronounced and chronic bronchitis did not significantly impact the risk of frequent exacerbations.
Impact of chronic bronchitis on all-cause and cause-specific mortality
During 5856 person-years of follow-up (median (IQR) 6.5 (4.0) years), 351 out of 924 COPD subjects
died: 92 (53.5%) among those with chronic bronchitis and 259 (34.4%) among those without chronic
bronchitis. COPD CB+ subjects had a worse survival than COPD CB− subjects, as illustrated in figure 2.
Compared to COPD CB− subjects, mortality risk was 1.3-fold higher in COPD CB+ subjects after
adjustment for age, sex and pack-years (HR 1.33, 95% CI 1.04–1.71) (table 4) and 1.2-fold in mild and
1.4-fold in moderate to severe COPD CB+ subjects (online supplementary table S4). Stratified for sex,
female CB+ subjects had a significantly worse survival than female CB− subjects, while the effect was less
pronounced in males and was no longer significant after adjustment for pack-years of cigarette smoking
(table 4).
The most frequent causes of death in COPD patients are shown in figure 3 and listed in more detail in
online supplementary table S5. Compared to COPD CB− subjects, COPD CB+ subjects deaths were more
TABLE 2 Association between chronic bronchitis (CB+ ) and forced expiratory volume in 1 s
(FEV1) decline
Model 1 Model 2
β (95% CI) p-value β (95% CI) p-value
Subjects n 270 259
COPD CB+ −35.2 (−57.9–−12.5) 0.002 −38.2 (−61.7–−14.6) 0.002
Male COPD CB+ −42.8 (−77.3–−8.2) 0.016 −42.8 (−78.1–−7.6) 0.018
Female COPD CB+ −29.4 (−58.7–−0.05) 0.050 −36.1 (−67.1–−5.2) 0.022
Annual lung function decline (mL·year-1) was calculated by dividing the difference between two FEV1
measurements by the number of years between the two measurements. β-values represent the additional
decline of FEV1 in chronic obstructive pulmonary disease (COPD) CB+ subjects compared to COPD subjects
without chronic bronchitis. Model 1: age and sex# adjusted; model 2: adjusted for age, sex# and pack-years
of cigarette smoking. #: unstratified analyses only.
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frequently due to respiratory-related causes including exacerbations, emphysema or pneumonia (figure 3).
COPD CB+ subjects had a more than two-fold increased risk of respiratory-related mortality compared to
COPD CB− subjects (HR 2.16, 95% CI 1.12–4.17 adjusted for age, sex and pack-years). Of note, mortality
due to lung cancer (bronchial carcinoma) was numerically higher, but did not significantly differ between
COPD subjects with and without chronic bronchitis (14.1% versus 12.4%) (figure 3).
Discussion
In this large, population-based cohort study, we demonstrated that COPD subjects with concomitant
chronic bronchitis (CB+) have a worse lung function at baseline and a subsequently larger lung function
decline during follow-up. In addition, COPD CB+ subjects experience significantly more exacerbations
during follow-up than COPD CB− subjects. Moreover, this study shows that CB+ subjects have a higher
mortality risk, especially COPD-related pulmonary death.
In our study, the prevalence of chronic bronchitis in subjects with COPD was 17.7%. The prevalence of
subjects in our study with chronic phlegm, with or without the presence of chronic cough, was 22.6%.
There is a considerable variability in the prevalence of chronic bronchitis among subjects with COPD
reported in other studies, ranging from 7.4% [19] to 74% [16]. Several variations of the classical definition
have been used to determine chronic bronchitis. In the PLATINO (Latin American Project for Research in
Pulmonary Obstruction) study, the prevalence doubled using a less stringent definition [19]. Furthermore,
a higher prevalence is reported in patient-based studies, which generally include few patients with mild
COPD, whereas population-based studies, such as the Rotterdam study incorporate an unselected COPD
population, which generally includes a larger proportion of subjects with mild COPD. Other factors that
influence the prevalence of chronic bronchitis among COPD subjects are smoking history and
TABLE 3 Association between chronic bronchitis (CB+) and the frequent exacerbator phenotype
Model 1 Model 2
OR (95% CI) p-value OR (95% CI) p-value
Subjects n 924 878
COPD CB+ 4.13 (2.82–6.04) <0.001 3.96 (2.67–5.88) <0.001
Male COPD CB+ 3.21 (1.90–5.42) <0.001 3.11 (1.82–5.31) <0.001
Female COPD CB+ 5.16 (2.94–9.05) <0.001 5.10 (2.83–9.20) <0.001
Model 1: age and sex# adjusted; model 2: adjusted for age, sex# and pack-years of cigarette smoking.
COPD: chronic obstructive pulmonary disease. #: unstratified analyses only.
FIGURE 2 Kaplan–Meier curve of
all-cause mortality according to
chronic obstructive pulmonary
disease without chronic bronchitis
(CB−, n=752) or with chronic
bronchitis (CB+, n=172).
1.0
0.8
0.6
0.4
0.2
0
Cu
m
ul
at
iv
e 
su
rv
iv
al
2000
Follow-up days
300010000 4000
CB–
CB+
https://doi.org/10.1183/13993003.02470-2016 6
COPD | L. LAHOUSSE ET AL.
geographical location [27, 28]. LU et al. [28] reported that living in a rural area was associated with an
increased risk of the development of chronic bronchitis.
A remarkable observation is that during the follow-up period, COPD CB+ subjects experienced an excess
lung function decline of 38.2 mL·year−1 compared to COPD CB− subjects. Considering that lung function
decline was determined in a subgroup of the population who survived until the next examination round
and who had two interpretable measurements, this difference in lung function decline is considerable. The
association of chronic bronchitis with a more rapid decline in lung function seemed slightly more
pronounced in male COPD CB+ subjects. In line with our findings, the population-based Copenhagen
City Heart Study reported an excess decline in FEV1 of 22.8 mL·year−1 for males and 12.6 mL·year−1 for
females during a 5-year follow-up in COPD CB+ subjects, whereas the patient-based ECLIPSE study did
not detect a difference in lung function decline in COPD patients with or without chronic bronchitis
during a 3-year follow-up, indicating the importance of a relevant follow-up period [8, 29]. In addition,
ALLINSON et al. [30] recently showed in a British cohort study with long-term follow-up, that the presence
of chronic bronchitis was associated with an additional 4.5 mL·year−1 decline in FEV1, irrespective of the
presence of COPD.
Conflicting results exist regarding the exacerbation rate in COPD CB+ patients. In our study, we observed
a significantly increased exacerbation rate and a four-fold increased risk of frequent exacerbations in
COPD CB+ subjects compared to COPD CB− subjects, especially in COPD subjects with moderate to
severe airflow limitation.
Furthermore, an increased exacerbation rate and an increased risk of frequent exacerbations was also
reported for COPD CB+ subjects in the COPDGene study and in a small study (n=70) in the UK [7, 14].
In contrast, the observations from the ECLIPSE study and a patient-based study in Spain did not
significantly associate chronic bronchitis to COPD exacerbations [12, 13, 15]. In the population-based
PLATINO study, the number of exacerbations in the past year were not significantly different for CB+
subjects compared to CB− subjects, but the percentage of subjects with at least one exacerbation in the
past year was significantly higher in the COPD CB+ group compared to the COPD CB− group [19].
TABLE 4 Association between chronic bronchitis (CB+) and the risk of all-cause death in
chronic obstructive pulmonary disease (COPD), additionally stratified according to sex
Model 1 Model 2
HR (95% CI) p-value HR (95% CI) p-value
Subjects n 924 878
COPD CB+ 1.45 (1.14–1.84) 0.002 1.33 (1.04–1.71) 0.024
Male COPD CB+ 1.32 (0.98–1.78) 0.072 1.22 (0.89–1.65) 0.212
Female COPD CB+ 1.69 (1.14–2.53) 0.010 1.57 (1.03–2.40) 0.036
Model 1: age and sex# adjusted; model 2: adjusted for age, sex# and pack-years of cigarette smoking. HR:
hazard ratio. #: unstratified analyses only.
Pulmonary
Cardiovascular
Other carcinoma
Other causes of death
Bronchial carcinoma
18.5%
22.8%
9.7%
a) b)
36.7%
12.4%
18.1%
23.2%
7.6%
14.1%
37.0%
FIGURE 3 Major causes of death according to chronic obstructive pulmonary disease a) without chronic
bronchitis (n=752) or b) with chronic bronchitis (n=172).
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Viral and bacterial infections account for the majority of exacerbations in COPD [31, 32]. Observations
from the Copenhagen City Heart Study indicate that subjects with chronic bronchitis are indeed more
vulnerable to pulmonary infections [8, 21]. This was also reported in the Lung Health Study, in which
subjects with chronic bronchitis reported significantly more lower-respiratory illness than those without
chronic bronchitis [33]. These reports strengthen the association between chronic bronchitis and COPD
exacerbations.
Potentially due to the increased vulnerability to exacerbations, we observed that COPD CB+ subjects are
more prone to pulmonary-related death compared to COPD CB− subjects. Furthermore, in this
population, we demonstrated that the presence of chronic bronchitis was associated with an increased
all-cause mortality risk of 33% in COPD subjects. Our results of increased mortality in COPD CB+
subjects are in line with those of PELKONEN et al. [20], reporting an even higher increase in both all-cause
and respiratory-related mortality.
Furthermore, we observed that female CB+ subjects had a significantly worse survival than female CB−
subjects. Previous studies have found sex differences in the impact of chronic bronchitis. For example, in
the Copenhagen City Heart Study, females with chronic bronchitis experienced more COPD-related
hospitalisations than males with chronic bronchitis [8]. In addition, results from the US Six Cities Study
indicated that females with chronic bronchitis have an increased risk of COPD-related death, compared to
males with chronic bronchitis [34]. Sex differences have been described in the effect of cigarette smoking
on lung function and hospitalisation for COPD, with females being more vulnerable to the effects of
cigarette smoking [35–37]. Nevertheless, quitting smoking remains key to resolving chronic bronchitis for
both males and females [38].
The strengths of our study are the general population-based setting, allowing us to investigate associations
in an unselected COPD population, the long-term follow-up and the prospective data collection. In the
Rotterdam study, moderate and severe exacerbations are indeed continuously and automatically registered
based on pharmacy-filled prescription data and a national hospitalisation register, which prevents recall
bias compared to self-reporting of the exacerbation frequency during the previous year in retrospective
studies. This does include a limitation, since we have no data on the frequency of mild exacerbations,
which are attended by an increase in regular medication.
A second limitation of our study is the fact that lung function was measured on prebronchodilator
spirometry and decline could only be determined in a subgroup of the COPD subjects, because an
interpretable spirometry at baseline was missing for a subset of subjects, a substantial proportion of the
subjects died before lung function could be measured a second time and not all subjects had two
interpretable lung function tests. However, even in this smaller group, the difference in lung function
decline between COPD subjects with and without chronic bronchitis was significant. Despite the
observation of similar results on lung function decline, exacerbation rate and mortality when the CB+
group meeting the strict criteria was extended to all subjects presenting with chronic phlegm production,
we do not feel empowered to advocate a broadening of the current definition of chronic bronchitis,
because even the very small deviations in effect estimates were towards the null, suggesting that these
criteria are indeed more strict in selecting the patients with worse outcomes. Finally, residual confounding
in the causal association between chronic bronchitis and worse health outcomes could still be present
since, for example, we did not collect information on upper airway infections or gastro-oesophageal reflux.
The results emphasise the importance of recognising chronic bronchitis as a COPD phenotype and the
need for therapies that specifically impact the devastating outcomes of COPD subjects with chronic
bronchitis. Roflumilast has been shown to be efficacious in patients with severe COPD, frequent
exacerbations and a chronic bronchitis phenotype [39]. High dose N-acetylcysteine treatment has been
suggested to prevent exacerbations in patients with COPD and chronic bronchitis [40]; however, potential
clinical benefits on respiratory health status, lung function or mortality are still controversial [41].
Advantages of novel or already approved antimicrobials are still under investigation (ClinicalTrials.gov
including NCT00538148 and NCT01071161).
In conclusion, we have shown that subjects with both COPD and chronic bronchitis have more decline in
lung function, experience more exacerbations and worse survival, driven by a higher risk of
respiratory-related mortality.
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